LLY
Eli Lilly and Company
LLY has the edge over SOPH overall, supported by stronger fundamentals and lower modeled downside.
SOPH
SOPHiA GENETICS S.A.
SOPH's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SOPH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
SOPH's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SOPH PE Valuation
SOPH has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SOPH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect SOPH's losses to shrink, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SOPH on earnings quality, reporting a profit while its opponent remains loss making.
SOPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.15 | -$0.05 |
| Q1 2026 | -$1.18 | -$0.18 |
| Q4 2025 | -$1.17 | -$0.22 |
| Q3 2025 | -$1.12 | -$0.03 |
| Q2 2025 | -$1.10 | -$0.08 |
| Q1 2025 | -$1.00 | +$0.12 |
| Q4 2024 | -$0.95 | +$0.27 |
| Q3 2024 | -$1.09 | -$0.02 |
SOPH is still losing money, but less than at its worst: $1.15 per share over the past year, against $1.51 at its worst in late 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over SOPH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over SOPH on profitability, with a higher operating margin.
SOPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $23.3M | +27% |
| Q1 2026 | $21.7M | +22% |
| Q4 2025 | $21.7M | +22% |
| Q3 2025 | $19.5M | +23% |
| Q2 2025 | $18.3M | +16% |
| Q1 2025 | $17.8M | +13% |
| Q4 2024 | $17.7M | +4% |
| Q3 2024 | $15.9M | -2.8% |
SOPH's revenue has grown year over year for seven quarters in a row: $23M last quarter, up 27% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -86% | +15 points |
| Q1 2026 | -80% | +11 points |
| Q4 2025 | -83% | +15 points |
| Q3 2025 | -92% | +5.1 points |
| Q2 2025 | -101% | -6.4 points |
| Q1 2025 | -90% | +29 points |
| Q4 2024 | -98% | +13 points |
| Q3 2024 | -97% | +4.6 points |
SOPH's operating margin was −86% last quarter, up 15 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over SOPH on cash generation, producing positive trailing cash flow while its opponent burns cash.
SOPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$10.4M | -$199K |
| Q1 2026 | -$17.1M | -$4.8M |
| Q4 2025 | -$9.3M | +$3.3M |
| Q3 2025 | -$8.9M | +$581K |
| Q2 2025 | -$10.2M | +$2.2M |
| Q1 2025 | -$12.2M | +$4.4M |
| Q4 2024 | -$12.5M | +$1M |
| Q3 2024 | -$9.5M | +$4.8M |
SOPH has burned cash in almost every quarter: −$46M over the past year, against −$44M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over SOPH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SOPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.8% | +2.7M shares |
| 1 year | +9.7% | +6.5M shares |
| 3 years | +14% | +9.3M shares |
| 5 years | +17% | +10.5M shares |
| Available history | +92% | +35.5M shares |
SOPH has 74M diluted shares, up 9.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
SOPH hasn't bought back shares in the past year.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SOPH Net Leverage
SOPH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SOPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.8 | Neutral |
| Stochastic | 56.5 | Neutral |
SOPH's weekly RSI is 59 (neutral) and its Stochastic is 57 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SOPH PE vs Healthcare Sector
SOPH has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
SOPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.57 | 3.8% above |
| 20 week MA | $7.25 | 8.4% above |
| 50 week MA | $5.87 | 34% above |
| 100 week MA | $4.68 | 68% above |
| 200 week MA | $4.35 | 81% above |
SOPH is in an uptrend: it's above all five of its weekly moving averages, and 81% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
SOPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $16.8 | $13.7 | -19% |
| 2022 | $13.7 | $2.85 | -79% |
| 2023 | $2.85 | $4.71 | +65% |
| 2024 | $4.71 | $3.36 | -29% |
| 2025 | $3.36 | $4.73 | +41% |
| 2026 YTD | $4.73 | $7.86 | +66% |
SOPH has the edge over LLY on returns for 2026, with the stronger performance.